Sepsis Alliance Clinical Community Sponsor Innovation Day
October 12 @ 1:00 pm - 3:30 pm
Date: October 12, 2022
Time: 1:00 – 3:30 pm ET / 10:00 am – 12:30 pm PT
Description: Join us for a half-day of sessions on innovations and best practices in sepsis care, each developed by the Sepsis Alliance Clinical Community sponsors. Each 30-minute session has its own registration link, so you can select those most applicable to your areas of focus—or join us for all three!
- Building ROI for your sepsis program;
- Reducing Blood Culture Contamination;
- Improving Sepsis Diagnosis with Precision Medicine Tools
Keep reading to learn more about the individual sessions and to register.
Presented by Wolters Kluwer
Time: 1:00 – 1:30 pm ET / 10:00 – 10:30 am PT
Description: In this sponsored webinar, learners will explore key considerations for building the ROI for their sepsis programs and investments, and will discuss how changes in people, process, and technology can drive improved sepsis outcomes.
Presented by Magnolia Medical Technologies
Time: 2:00 – 2:30 pm ET / 11:00 – 11:30 am PT
Description: Join this sponsored webinar to learn more about Baylor Scott & White – Centennial’s success and how its experience with practice change and evidence-based technology supported diagnostic, antimicrobial, and financial stewardship.
Presented by Immunexpress
Time: 3:00 – 3:30 pm ET / 12:00 – 12:30 pm PT
Description: Dascena’s machine learning algorithm, InSight, is a non-device clinical decision support (CDS) tool used by healthcare providers to identify patient data patterns that may be missed by a human. InSight can automatically recognize patients who are at risk of sepsis up to 4 hours before onset with high accuracy. This helps inform physicians and care teams early, so they can take appropriate action.
Clinical evidence and scientific rigor are at the core of Dascena’s development. During our real-world clinical trial, hospitals saw an average 39.5% reduction of in-hospital mortality, a 32.3% reduction of hospital length of stay, and a 22.7% reduction of 30-day readmission rates for sepsis-related patient stays when using InSight.